Viracta Therapeutics Insiders
VIRXDelisted Stock | USD 0.03 0 7.38% |
Viracta Therapeutics employs about 40 people. The company is managed by 16 executives with a total tenure of roughly 94 years, averaging almost 5.0 years of service per executive, having 2.5 employees per reported executive. Break down of Viracta Therapeutics' management performance can provide insight into the company performance.
Mark Rothera CEO President CEO |
Viracta |
Viracta Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.572) % which means that it has lost $0.572 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0867) %, meaning that it created substantial loss on money invested by shareholders. Viracta Therapeutics' management efficiency ratios could be used to measure how well Viracta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Viracta Therapeutics Workforce Comparison
Viracta Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,877. Viracta Therapeutics holds roughly 40.0 in number of employees claiming about 2.13% of equities under Health Care industry.
Viracta Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Viracta Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Viracta Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Viracta Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Viracta Therapeutics Notable Stakeholders
A Viracta Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Viracta Therapeutics often face trade-offs trying to please all of them. Viracta Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Viracta Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mark Rothera | President CEO | Profile | |
Daniel CPA | COO, CFO | Profile | |
Cheryl Madsen | Senior Affairs | Profile | |
Daniel Chevallard | COO CFO | Profile | |
Thalia MD | CoFounder | Profile | |
Patric MBA | Senior Strategy | Profile | |
Ronald MD | CoFounder Consultant | Profile | |
George Hillman | CoFounder | Profile | |
Robert Williams | CoFounder | Profile | |
Robert McRae | Vice Alliances | Profile | |
Ayman ElGuindy | Chief Officer | Profile | |
Stewart Brown | Senior Counsel | Profile | |
Susan MD | Scientific Consultant | Profile | |
Michael Faerm | Chief Officer | Profile | |
Lisa Rojkjaer | Chief Officer | Profile | |
Biljana PharmD | Senior Development | Profile |
About Viracta Therapeutics Management Performance
The success or failure of an entity such as Viracta Therapeutics often depends on how effective the management is. Viracta Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Viracta management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Viracta management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California. Viracta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people.
Please note, the imprecision that can be found in Viracta Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Viracta Therapeutics. Check Viracta Therapeutics' Beneish M Score to see the likelihood of Viracta Therapeutics' management manipulating its earnings.
Viracta Therapeutics Workforce Analysis
Traditionally, organizations such as Viracta Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Viracta Therapeutics within its industry.Viracta Therapeutics Manpower Efficiency
Return on Viracta Therapeutics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.3M | |
Net Loss Per Executive | 3.2M | |
Working Capital Per Employee | 414.8K | |
Working Capital Per Executive | 1M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Viracta Pink Sheet
If you are still planning to invest in Viracta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viracta Therapeutics' history and understand the potential risks before investing.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Global Correlations Find global opportunities by holding instruments from different markets |